Cancer and HIV Treatments

Since 1996 and the introduction of the highly active antiretroviral therapy (HAART), we observe an increasing life expectancy in persons living with HIV (PLHIV) worldwide with a changing in death profile causes. Concerning the HIV infection, the World Health Organization (WHO) recommends the use of HAART. However, some disparities exist between countries, because of treatment access and local recommendations. The WHO recommends to start HAART when CD4 lymphocyte count is under 500/mm3. No specific references exist for the cancer treatments in PLHIV, while this is a fragile population with morbidities requiring more attention.